Anderson KC - Search Results

1

The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.

Treon SP, Anderson KC. Treon SP, et al. Among authors: anderson kc. Semin Oncol. 2000 Dec;27(6 Suppl 12):79-85. Semin Oncol. 2000. PMID: 11226004 Review.

2

Interleukin-6 in multiple myeloma and related plasma cell dyscrasias.

Treon SP, Anderson KC. Treon SP, et al. Among authors: anderson kc. Curr Opin Hematol. 1998 Jan;5(1):42-8. Curr Opin Hematol. 1998. PMID: 9515202 Review.

3

Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.

Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC. Treon SP, et al. Among authors: anderson kc. Semin Oncol. 1999 Oct;26(5 Suppl 14):97-106. Semin Oncol. 1999. PMID: 10561024

4

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.

Treon SP, Shima Y, Grossbard ML, Preffer FI, Belch AR, Pilarski LM, Anderson KC. Treon SP, et al. Among authors: anderson kc. Ann Oncol. 2000;11 Suppl 1:107-11. Ann Oncol. 2000. PMID: 10707790 Review.

5

Immunotherapeutic strategies for the treatment of plasma cell malignancies.

Treon SP, Raje N, Anderson KC. Treon SP, et al. Among authors: anderson kc. Semin Oncol. 2000 Oct;27(5):598-613. Semin Oncol. 2000. PMID: 11049026 Review.

6

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC. Treon SP, et al. Among authors: anderson kc. J Immunother. 2001 May-Jun;24(3):263-71. J Immunother. 2001. PMID: 11394505

7

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.

Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. Treon SP, et al. Among authors: anderson kc. J Immunother. 2001 May-Jun;24(3):272-9. J Immunother. 2001. PMID: 11394506

8

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.

Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Treon SP, et al. Among authors: anderson kc. Ann Oncol. 2004 Oct;15(10):1481-3. doi: 10.1093/annonc/mdh403. Ann Oncol. 2004. PMID: 15367407 Free article. Clinical Trial.

9

Extended rituximab therapy in Waldenström's macroglobulinemia.

Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR; Waldenström's Macroglobulinemia Clinical Trials Group. Treon SP, et al. Among authors: anderson kc. Ann Oncol. 2005 Jan;16(1):132-8. doi: 10.1093/annonc/mdi022. Ann Oncol. 2005. PMID: 15598950 Free article. Clinical Trial.

10

Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells.

Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KC. Urashima M, et al. Among authors: anderson kc. Blood. 1997 Jul 1;90(1):279-89. Blood. 1997. PMID: 9207463 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,226 results

Search Page

Filters